Recent News

• 05.29.2025 - NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
• 05.29.2025 - NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
• 05.29.2025 - NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
• 05.01.2025 - NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
• 05.01.2025 - NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
• 05.01.2025 - NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
• 04.10.2025 - 24th Annual Needham Virtual Healthcare Conference
• 04.10.2025 - 24th Annual Needham Virtual Healthcare Conference
• 04.04.2025 - NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Recent Filings

• 05.19.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.19.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.01.2025 - 8-K Current report
• 05.01.2025 - EX-99.1 EX-99.1
• 05.01.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.25.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.25.2025 - DEF 14A Other definitive proxy statements
• 04.15.2025 - PRE 14A Other preliminary proxy statements
• 04.10.2025 - 8-K Current report